Fujikawa Takahisa, Tanaka Akira, Abe Toshihiro, Yoshimoto Yasunori, Tada Seiichiro, Maekawa Hisatsugu
Department of Surgery, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku, Kitakyushu, Fukuoka, 802-8555, Japan,
World J Surg. 2015 Jan;39(1):139-49. doi: 10.1007/s00268-014-2760-3.
Antiplatelet agents given to prevent thromboembolic disease are frequently withdrawn prior to surgical procedures to reduce bleeding complications. This action may expose patients to increased thromboembolic morbidity and mortality.
A series of 2012 patients who had undergone gastroenterologic surgery between January 2005 and June 2010 at our institution were reviewed. Among this cohort, antiplatelet therapy (APT) was used in 519 patients (25.8 %). The perioperative management included interruption of APT 1 week before surgery and early postoperative reinstitution in patients at low thromboembolic risk, although APT was maintained until surgery in those at high thromboembolic risk. Bleeding and thromboembolic complications, as well as other outcome variables, were assessed in patients with and without APT.
Among 519 patients with APT, 99 (19.1 %) underwent multidrug APT. Among them, 124 (23.9 %) required preoperative continuation of APT. None suffered from excessive bleeding intraoperatively. There were 19 thromboembolic events (0.9 %) in the whole cohort. Postoperative bleeding complications occurred in 37 patients (1.8 %). Multivariate analysis showed that increased postoperative bleeding complications were independently associated with multidrug APT [hazard ratio (HR) 4.3, p = 0.014], high-risk surgical procedures (HR 3.5, p = 0.003), and perioperative heparin bridging (HR 2.8, p = 0.029). High-risk surgery (HR 8.3, p < 0.001) and poor performance status (HR 4.9, p = 0.005)--but neither APT nor anticoagulation use--were significant prognostic factors for thromboembolic complications.
Satisfactory outcomes were obtained during gastroenterologic surgery under rigorous perioperative management, including single-agent APT continuation in patients at high thromboembolic risk. Patients treated with multidrug APT still represent a challenging group, however, and need to be carefully managed to prevent perioperative complications.
为预防血栓栓塞性疾病而使用的抗血小板药物在外科手术前常被停用,以减少出血并发症。这一举措可能会使患者面临更高的血栓栓塞性发病和死亡风险。
回顾了2005年1月至2010年6月在我院接受胃肠外科手术的2012例患者。在该队列中,519例患者(25.8%)使用了抗血小板治疗(APT)。围手术期管理包括对血栓栓塞风险低的患者在手术前1周中断APT,并在术后早期重新用药,而对于血栓栓塞风险高的患者,APT一直维持到手术。对使用和未使用APT的患者评估出血和血栓栓塞并发症以及其他结局变量。
在519例接受APT的患者中,99例(19.1%)接受了多种药物的APT。其中,124例(23.9%)需要在术前继续使用APT。术中无一例发生大出血。整个队列中有19例血栓栓塞事件(0.9%)。术后出血并发症发生在37例患者(1.8%)中。多变量分析显示,术后出血并发症增加与多种药物的APT独立相关[风险比(HR)4.3,p = 0.014]、高风险手术(HR 3.5,p = 0.003)以及围手术期肝素桥接(HR 2.8,p = 0.029)。高风险手术(HR 8.3,p < 0.001)和较差的身体状况(HR 4.9,p = 0.005)——而非APT的使用或抗凝药物的使用——是血栓栓塞并发症的显著预后因素。
在严格的围手术期管理下,胃肠外科手术取得了满意的结果,包括对血栓栓塞风险高的患者继续使用单药APT。然而,接受多种药物APT治疗的患者仍然是一个具有挑战性的群体,需要仔细管理以预防围手术期并发症。